ArticleScientific reports2025
Analytical and clinical comparison of four SLE-associated autoantibodies in different autoimmune diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diagnostic Value of ANA Titer, Anti-ds-DNA, Anti-nRNPSm, and Sm Antibodies in Early Atypical Systemic Lupus Erythematosus.Pakistan journal of medical sciences · 2026Article
- Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.Biomedicines · 2026Article
- Toward Precision Health in Autoimmunity and Immune-Related Adverse Events: The Autoantibody Reactome, Spatial Omics, and Multimodal Data Integration.Biomedicines · 2026Article
- Alterations in peripheral blood B cell subsets and their clinical significance in systemic lupus erythematosus.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Autoantibodies associated with systemic lupus erythematosus (SLE) are often present in patients with a variety of autoimmune diseases, affecting the diagnosis and differentiation of the diseases. In this study, the positive rates and diagnostic efficiencies of anti-dsDNA, anti-nucleosome, anti-ribosomal P and anti-C1q antibodies were analysed in 216 SLE patients, 323 rheumatoid arthritis (RA) patients, 87 Sjogren's syndrome (SS) patients, 45 patients with other autoimmune diseases (OAD) and 52 healthy controls (HC). In addition to being high in SLE patients, the serum levels of anti-dsDNA and anti-nucleosome antibodies were also significantly higher in SS patients compared with OAD (P = 0.008, < 0.001). The ROC-AUCs for the four SLE-associated autoantibodies in distinguishing SLE patients from SS patients were lower than those in distinguishing SLE patients from HC. Therefore, SLE-associated autoantibody-positive SS patients represent a less studied and heterogeneous population, as these antibodies are also present in approximately 15% of all SS patients. Compared with SLE-associated autoantibody-negative SS patients, SS patients who were positive for SLE-associated autoantibodies were more likely to be positive for anti-nRNP/Sm autoantibodies (30.77% vs. 4.05%, P = 0.001). Oral ulcerations, rampant dental and pulmonary involvement were more frequent in SS patients who were positive for SLE-associated autoantibodies than in those who were negative for these autoantibodies (P = 0.018, 0.004 and < 0.001). In conclusion, SLE-associated autoantibody-positive SS patients represent a heterogeneous population, characterized by unique autoantibody profiles and clinical manifestations. This study may provide new insights for diagnostic refinement between SLE and SS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.